Biodesix (BDSX) Operating Expenses (2019 - 2026)

Biodesix (BDSX) has reported Operating Expenses for 8 consecutive years, with $31.8 million the latest figure, recorded in Q1 2026.

• Operating Expenses for Q1 2026 came in at $31.8 million, up 17.21% year-over-year; the trailing twelve-month figure through Mar 2026 was $92.2 million (down 40.59% YoY), and the FY2025 annual result was $6.7 million, down 93.69% from the prior year.
• Operating Expenses was $31.8 million for Q1 2026 at Biodesix, up from $1.9 million in the prior quarter.
• Over five years, Operating Expenses peaked at $100.6 million in Q4 2024 and troughed at $1.4 million in Q3 2024.
• Average Operating Expenses over 5 years is $25.2 million, with a median of $22.8 million recorded in 2023.
• The widest YoY moves for Operating Expenses: up 1942.45% in 2025, down 98.08% in 2025.
• Over 5 years, Operating Expenses stood at $23.5 million in 2022, then retreated by 8.34% to $21.5 million in 2023, then jumped by 367.13% to $100.6 million in 2024, then plunged by 98.08% to $1.9 million in 2025, then soared by 1543.69% to $31.8 million in 2026.
• Per Business Quant data, the three most recent Operating Expenses figures were $31.8 million in Q1 2026, $1.9 million in Q4 2025, and $28.8 million in Q3 2025.